Creating new incentive models and transparently sharing data in a way that changes behaviors are 2 ways to reduce low-value care in the health care system, explains Ken Cohen, MD, director of translational research for Optum Care.
Creating new incentive models and transparently sharing data in a way that changes behaviors are 2 ways to reduce low-value care in the health care system, explains Ken Cohen, MD, director of translational research for Optum Care.
Transcript
How can we do a better job of removing low-value, wasteful care from the health care system?
The quick and easy answer is you stop paying for it. There’s not been a lot of will to do that, so, the question is: what else can you do? There's really 2 things. One is, you change how you pay specialists. So, 93% of the specialists in this country are strictly volume based, and that does not foster a value-based care environment. You need to build incentive models so that about a third to up to 50% of the revenue that a specialist makes is based on incentives for value-based care, for population health management, and not based for volume. It's a tricky thing to do, because the specialty incentive model needs to look completely different for each specialty. They have to be designed specialty specific. It's difficult, not impossible. We're actually hard at work doing that now.
The other thing that you can do is transparently share data. If you start measuring high-value care, and low-value care, and array that on unblinded transparent reports and share it both with PCPs [primary care providers] and specialists, 2 things happen. Number 1, PCPs start migrating referrals to high-value specialists. Number 2, the folks that are not high up on those lists begin to alter their care patterns so that they can preserve those referrals.
Both of those have actually turned out to be effective methods.
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen